ELAN vs. BNTX, TEVA, SMMT, GMAB, ITCI, RDY, MRNA, ASND, VTRS, and QGEN
Should you be buying Elanco Animal Health stock or one of its competitors? The main competitors of Elanco Animal Health include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.
Elanco Animal Health vs. Its Competitors
BioNTech (NASDAQ:BNTX) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.
Elanco Animal Health has a net margin of 4.60% compared to BioNTech's net margin of -15.16%. Elanco Animal Health's return on equity of 6.78% beat BioNTech's return on equity.
BioNTech has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500.
In the previous week, BioNTech had 21 more articles in the media than Elanco Animal Health. MarketBeat recorded 25 mentions for BioNTech and 4 mentions for Elanco Animal Health. BioNTech's average media sentiment score of 0.51 beat Elanco Animal Health's score of 0.40 indicating that BioNTech is being referred to more favorably in the media.
BioNTech has higher earnings, but lower revenue than Elanco Animal Health. BioNTech is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.
BioNTech received 7 more outperform votes than Elanco Animal Health when rated by MarketBeat users. However, 54.96% of users gave Elanco Animal Health an outperform vote while only 47.04% of users gave BioNTech an outperform vote.
BioNTech presently has a consensus price target of $138.25, indicating a potential upside of 29.72%. Elanco Animal Health has a consensus price target of $15.17, indicating a potential upside of 9.74%. Given BioNTech's stronger consensus rating and higher probable upside, analysts plainly believe BioNTech is more favorable than Elanco Animal Health.
15.5% of BioNTech shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 0.9% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
BioNTech beats Elanco Animal Health on 10 of the 19 factors compared between the two stocks.
Get Elanco Animal Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELAN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ELAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elanco Animal Health Competitors List
Related Companies and Tools
This page (NYSE:ELAN) was last updated on 6/13/2025 by MarketBeat.com Staff
Buy ELAN Stock Free ELAN Stock Alerts